IP Library Granted Patent US 10,222,376
Granted Patent B2
US 10,222,376 · App. 15/796,201 · Granted Mar 5, 2019

Methods and compositions for identifying leukemic stem cells

Inventor: Jonathan M. Gerber (Charlotte, NC)
Assignee: The Charlotte-Mecklenburg Hospital Authority
G01N33/57426C12Q1/6886C12Q2600/112C12Q2600/156G01N2333/70596G01N2333/90203G01N2333/91148G01N2333/96494
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,222,376
App. No.
15/796,201
Granted
Mar 5, 2019
Kind
B2
Abstract

The present invention provides methods and compositions for identifying leukemic stem cells.

Claims (11)

1. A method of guiding treatment of a subject having or diagnosed with acute lymphocytic leukemia (ALL) or lymphoid blast crisis chronic myeloid leukemia (LBC CML) at increased risk of relapse after chemotherapy alone, comprising:

(a) obtaining a biological cell sample from the subject;

(b) isolating mononuclear cells from the sample of (a);

(c) allowing the cells of (b) to take up a fluorescence substrate for the enzyme aldehyde dehydrogenase (ALDH) and labeling the cells with an anti-CD34 monoclonal antibody and an anti-CD38 monoclonal antibody, in combination with an anti-CD19 monoclonal antibody;

(d) isolating CD34 + CD38 − mononuclear cells from the cells of (c) using flow cytometry;

(e) measuring the ALDH activity of the cells of (d);

(f) comparing the levels of ALDH activity in the cells of (e) with the levels of ALDH activity in the cells of a reference sample; and

(g) identifying cells of (f) that have a high level of ALDH activity (CD34 + CD38 31 ALDH high ) in the sample from the subject when compared to the level of ALDH activity of the CD34 + CD38 − cells in the reference sample; and

h) assaying the CD34 + CD38 − ALDH high cells identified in (g) for the presence or absence of CD19 on the surface of the CD34 + CD38 − ALDH high cells, wherein the presence of CD19 cells on the surface of the CD34 + CD38 − ALDH high cells identifies the subject as being more likely to relapse after chemotherapy alone relative to a subject lacking said cells; and

(i) administering a treatment to the subject, selected from immunotherapy, an anti-body based therapy, hematopoietic stem cell transplantation, and/or chimeric antigen receptor T cell therapy with or without chemotherapy to decrease the subject's risk of relapse.

2. The method of claim 1 , further comprising assaying the cells of (d) for the presence or absence of CD3, CD5, CD20, CD22, CD25, CD33, CD40, CD42, CD44, CD45, CD47, CD90, CD96, CD123, CD133, CD138, CD235a, IL1RAP, PD1, and/or PDL1 on the cells.

Assignments (2)
CHANGE OF NAME Recorded Dec 7, 2018
From: THE CHARLOTTE MECKLENBURG HOSPITAL AUTHORITY D/B/A CAROLINAS HEALTHCARE SYSTEM
To: THE CHARLOTTE MECKLENBURG HOSPITAL AUTHORITY D/B/A ATRIUM HEALTH
Reel/Frame 047702/0504 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2018
From: GERBER, JONATHAN M.
To: THE CHARLOTTE MECKLENBURG HOSPITAL AUTHORITY D/B/A CAROLINAS HEALTHCARE SYSTEM
Reel/Frame 044599/0832 →
Continuity (2)
Provisional Application 62417238 · Nov 3, 2016
Related Publication 20180120321A1 · May 3, 2018
Cited By (2)
US 12,350,347 US 12,492,980